These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17287904)

  • 21. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
    Paraná R; Schinoni MI; de Freitas LA; Codes L; Cruz M; Andrade Z; Trepo C
    Liver Int; 2006 Nov; 26(9):1148-54. PubMed ID: 17032416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
    Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
    Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.
    Marcellin P; Horsmans Y; Nevens F; Grange JD; Bronowicki JP; Vetter D; Purdy S; Garg V; Bengtsson L; McNair L; Alam J
    J Hepatol; 2007 Oct; 47(4):476-83. PubMed ID: 17629590
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
    Napoli N; Giannelli G; Antonaci A; Antonaci S
    J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy.
    Liang CC; Liu CH; Chung CS; Lin CK; Su TH; Yang HC; Liu CJ; Chen PJ; Chen DS; Kao JH
    J Infect Dis; 2015 May; 211(9):1429-36. PubMed ID: 25387585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients.
    Roomer R; Bergmann JF; Boonstra A; Hansen BE; Haagmans BL; Kwadijk-de Gijsel S; van Vuuren AJ; de Knegt RJ; Janssen HL
    Antivir Ther; 2012; 17(3):509-17. PubMed ID: 22300892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
    Helal GK; Gad MA; Abd-Ellah MF; Mahgoup EM
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):553-7. PubMed ID: 26872109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Very early viral kinetics on interferon treatment in chronic hepatitis C virus genotype 4 infection.
    Jessner W; Gschwantler M; Formann E; Gurguta C; Watkins-Riedel T; Wrba F; Ferenci P
    Antivir Ther; 2008; 13(4):581-9. PubMed ID: 18672537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin.
    Oze T; Hiramatsu N; Yakushijin T; Kurokawa M; Igura T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Yoshida Y; Tatsumi T; Ohkawa K; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Viral Hepat; 2009 Aug; 16(8):578-85. PubMed ID: 19552663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.
    Macías J; López-Cortés LF; Téllez F; Recio E; Ojeda-Burgos G; Ríos MJ; Rivero-Juárez A; Delgado M; Rivas-Jeremías ; Pineda JA
    PLoS One; 2015; 10(12):e0143492. PubMed ID: 26640956
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).
    Couzigou P; Pérusat S; Bourlière M; Trimoulet P; Poynard T; Leroy V; Marcellin P; Foucher J; Bronowicki JP; Chêne G;
    J Gastroenterol Hepatol; 2013 Feb; 28(2):329-34. PubMed ID: 23190183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
    Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
    J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
    Gentile I; Viola C; Reynaud L; Borrelli F; Cerini R; Ciampi R; Piazza M; Borgia G
    J Interferon Cytokine Res; 2005 May; 25(5):283-5. PubMed ID: 15871666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
    Akhan SC; Kalender B; Ruzgar M
    Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin.
    Ueyama M; Nakagawa M; Sakamoto N; Onozuka I; Funaoka Y; Watanabe T; Nitta S; Kiyohashi K; Kitazume A; Murakawa M; Nishimura-Sakurai Y; Sekine-Osajima Y; Itsui Y; Azuma S; Kakinuma S; Watanabe M;
    Antivir Ther; 2011; 16(7):1081-91. PubMed ID: 22024524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
    Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
    J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan.
    Aziz H; Gil ML; Waheed Y; Adeeb U; Raza A; Bilal I; Athar MA
    Infect Genet Evol; 2011 Apr; 11(3):640-5. PubMed ID: 21316487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.